NCT02921815View on ClinicalTrials.gov

A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment

CompletedOBSERVATIONAL
Enrollment

84

Participants

Timeline

Start Date

March 3, 2011

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Myelodysplastic SyndromesLeukemia, Myeloid, Acute
Trial Locations (1)

651-0072

Shinko Hospital, Kobe

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT02921815 - A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment | Biotech Hunter | Biotech Hunter